Tech Company Financing Transactions
Nusano Funding Round
Nusano, based in Valencia, secured $115 million from Wasatch Equity Partners, BrightEdge and Section 32.
Transaction Overview
Company Name
Announced On
10/1/2024
Transaction Type
Venture Equity
Amount
$115,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to support the initial product launches of non-carrier-added lutetium-177 (n.c.a. Lu-177) and actinium-225 (Ac-225).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
28575 Livingston Ave
Valencia, CA 91355
USA
Valencia, CA 91355
USA
Phone
Website
Email Address
Overview
Nusano's patented technologies and methods are poised to transform radioisotope production and usher in an exciting new era in cancer care. When it opens, our state-of-the-art facility in West Valley City, Utah will produce radioisotopes quickly, efficiently, and affordably. This will make desperately needed resources available to hospitals and cancer clinics around the world and offer those with life-threatening diseases hope for a healthier tomorrow.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Lowe
Chief Financial Officer
Pushkar Bedekar
Chief Scientific Officer
Chris Ignace
Chief Technical Officer
Glenn Rosenthal
VP - Bus. Development
Rohan Jain
VP - Bus. Development
Jzaneen Lalani
VP - Human Resources
Maggie Kruse
VP - Product Management
Kevin Haehl
VP - Product Management
Howard Lewin
Browse more venture capital transactions:
Prev: 10/1/2024: Air Doctor venture capital transaction
Next: 10/1/2024: DocJuris venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. VC transactions reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs